5 January 2024
Freshfields’ Litigation Team Defeats Shareholder Effort to Challenge Sumitovant’s $2.9bn Acquisition of Myovant
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| David Yury Livshiz | Freshfields | Partner | Litigation | Not stated |
| Boris Feldman | Freshfields | Partner | Litigation | Not stated |
| Peter J. Linken | Freshfields | Counsel | Litigation | Not stated |
| Elena Hadjimichael | Freshfields | Associate | Litigation | Not stated |
| Nathan A. Hembree | Freshfields | Associate | Litigation | Not stated |
| Abby Kritta | Freshfields | Associate | Litigation | Not stated |
| Jake Rothstein | Freshfields | Associate | Litigation | Not stated |
| Raul Orozco | Freshfields | Associate | Litigation | Not stated |
Stated terms
- Stated value
- USD 2.90bn ($2.9 billion dollar)
- What the figure measures
- Total transaction value
- Client
- Not stated
- Counterparties
- Sumitovant Biopharma Limited (Buy-side)
Myovant Sciences Limited (Sell-side)